11 news items
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
nucleotide 6-thio-2'-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
MAIA
7 Jun 24
cancer cell telomeres and stimulate immune responses marks a significant advancement in the fight against this devastating disease.MAIA's Lead
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
(ASCO) 2024 Annual Meeting, show a remarkable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% when THIO is paired
MAIA Biotechnology Announces Year-to-Date Highlights And Achievements, Including Clinical Progress Of Lead Candidate THIO, A First-In-Class Cancer Telomere Targeting Agent For Non-Small Cell Lung Cancer (NSCLC)
MAIA
6 Jun 24
-of-care treatments in non-small cell lung cancer (NSCLC)38% overall response rate (ORR) in third-line (3L) setting (THIO 180mg) vs. ~6
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA
6 Jun 24
response rate (ORR) in third-line (3L) setting (THIO 180mg) vs. ~6% for currently available treatments in a similar population
dwy61u6w5a auob0igekr6b0mixf
CORT
HALO
MAIA
6 Jun 24
overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% with the THIO + cemiplimab combination in third-line treatments
yo3vzhpse dgtnqce7
MAIA
4 Jun 24
control and overall response rates exceed reported standard-of-care data in third line treatment
ka16ub4gqyvlzrtp903b5igplx mnrwp45e
AFMD
ALBT
BPTH
4 Jun 24
functions by inducing telomeric DNA damage and boosting cancer-specific immune responses, potentially offering a new pathway for cancer treatment where
4eyqolldvzdo3kuynf1aftl5bw6 lh5py7ysys
MAIA
22 May 24
responses in subjects with advanced NSCLC who did not respond or progress after first-line treatment with a checkpoint inhibitor, a type of drug that blocks
did5n0j1yq6b8wn8w5zmdhgjo2jopyr9d59
MAIA
17 May 24
responses. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment
juk3ikizd09i6950pw61jaqqh4ymas6knwrtw xmpycn67ujlnu8ahmuzbn
MAIA
5 Apr 24
, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses
- Prev
- 1
- Next